🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06727890
Starting soon Phase 4

Compound Danshen Dripping Pill for Diabetic Microvascular Angina

NCT06727890 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Hospital of Shandong University
Phase
Phase 4
Started
2025-01-01
Last updated
2024-12-11

Condition(s) studied

Diabetic Microvascular Angina

Investigational drug(s) / intervention(s)

Danshen Dripping PillPlacebo

Danshen Dripping Pill: Danshen Dripping Pill, 10 pills once, three times a day

Placebo: Placebo, 10 pills once, three times a day

Study summary

To investigate the efficacy and safety of Compound Danshen Dripping Pill in patients with diabetic microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Compound Danshen Dripping Pill on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: History of type 2 diabetes ≧5 years; Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks; Coronary normal or stenosis \<50%; Ischemic depression in ST segment during resting or exercise; Coronary flow reserve (CFR) of the anterior descending coronary artery \< 2.0, or CFR ≧2.0 but acetylcholine activation test is positive; Subjects or their guardians agreed to participate in this study. Exclusion Criteria: Previous myocardial infarction or PCI or CABG treatment; Severe arrhythmia; Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm; Familial hypercholesterolemia; Takayasu arteritis, Kawasaki disease or coronary artery malformation; Pregnant or nursing, or having the intention to give birth within one year; Hepatic or renal dysfunction; Allergic to contrast agents or traditional Chinese medicines; Patients who participated in clinical research of other drugs within 3 months before being selected.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Qilu Hospital of Shandong University Jinan Shandong
Central Hospital Affiliated to Shandong First Medical University Jinan Shandong
The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianfoshan Hospital Jinan Shandong

More Qilu Hospital of Shandong University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06727890 on ClinicalTrials.gov ↗ ← All trials in China